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The central and renal hemodynamic effects of nifedipine
were evaluated in nine patients with severe chronic
congestive heart failure. Oral nifedipine (34 ± 22 mg,
mean ± standard deviation) was associated with a de-
crease in systemic vascular resistance from 1,748 ± 436
to 1,321 ± 302 dynes-s-cmr" (p < 0.001) and mean
arterial blood pressure from 96 ± 11 to 87 ± 6 mm Hg
(p < 0.05) and with an increase in cardiac output from
4.2 ± 1.1 to 4.9 ± 1.2 liters/min (p < 0.001). Although
renal vascular resistance decreased from 11,988 ± 2,256
to 10,286 ± 3,011 dynes-s-cm " (p < 0.05), no signifi-
cant change was seen in renal blood flow (599 ± 120 to
640 ± 162 ml/min), glomerular filtration rate (62 ± 18
to 62 ± 17 mIlmin), filtration fraction (18 ± 5 to 17 ±
6%), the ratio of renal/systemic vascular resistance (7.0
:!: 1.0 to 7.9 ± 1.8) and the ratio of renal blood
flow/cardiac output (0.15 ± 0.02 to 0.13 ± 0.03).
Intravenous hydralazine (10 ± 5 mg), given to eight
of the patients in a randomized crossover design, re-
sulted in a larger increase in cardiac output than did
nifedipine (38 ± 7 versus 19 ± 10%, P < 0.001) and
in an increase in total renal blood flow from 570 ± 152
Congestive heart failure is associated with major changes
in regional distribution of cardiac output. Impairment of
renal flow is commonly seen and is partially responsible for
the retention of sodium and water in patients with heart
failure (1,2), Peripheral vasodilation with various vasodi-
lators has been shown to have a beneficial effect on central
hemodynamics and has become standard therapy for severe
heart failure. However, the response of the renal circulation
to this form of therapy varies markedly according to the
drug used (3-5), Nifedipine exerts a strong arteriolar di-
latory effect by virtue of its antagonistic action to calcium
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to 645 ± 174 ml/min (p < 0.001). Renal vascular re-
sistance decreased from 12,080 ± 2,934 to 10,153 ±
2,372 dynes-s-cmr" (p < 0.001). The ratio renal/systemic
vascular resistance, however, increased from 6.9 ± 0.9
to 8.5 ± 1.3 (p < 0.001), and the ratio of renal blood
flow/cardiac output decreased from 0.15 ± 0.02 to 0.13
± 0.03 (p < 0.001). In spite of the improvement in renal
blood flow, no change was noted in glomerular filtration
rate (57 ± 18 to 57 ± 11 ml/min) or filtration fraction
(16 ± 3 to 15 ± 3%).
This study demonstrates that the strong arteriolar
vasodilation of nifedipine involves the renal circulation
and decreases abnormally elevated renal vascular re-
sistance. This effect, however, does not lead to an im-
provement of renal blood flow or glomerular filtration
rate. Vasodilation with hydralazine results in significant
improvement of renal perfusion, although renal blood
flow does not increase proportionately as much as the
total cardiac output. Despite improvement in renal per-
fusion, hydralazine, similar to nifedipine, does not in-
crease glomerular filtration rate.
influx across the vascular smooth muscle cell membrane
(6). The central hemodynamic effect of the drug has been
documented recently in patients with severe heart failure
(7,8). Little is known, however, about the specific effect
of nifedipine on the renal vascular bed in patients with heart
failure.
The present study was designed to assess the short-term
renal hemodynamic response to nifedipine in relation to its
central cardiocirculatory effects and compare it with that of
hydralazine in the same patients with chronic severe conges-
tive heart failure.
Methods
Patients. Nine patients (eight men and one woman) were
studied. All patients were admitted because of worsening
of chronic severe heart failure. Their ages ranged from 20
to 76 years (mean ± standard deviation 54 ± 19). The
cause of heart failure was ischemic heart disease in two
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patients and congestive dilated cardiomyopathy in seven
patients . The diagnosis of left ventricular dysfunction was
established by history , physical examination, electrocardio-
gram, chest X-ray film and echocardiogram in all patients
and was confirmed by cardiac catheterization in six of the
nine patients. Left ventricular ejection fraction was studied
in eight patients , either by contrast or radionuclide ventric-
ulography and ranged from 0.10 to 0.24 (mean 0.16 ±
0.05) . All patients were in New York Heart Association
functional classes III and IV and were in clinically stable
condition at bed rest for at least 3 days . All patients con-
tinued their usual doses of digitalis; however, diuretic agents
and long-acting vasodilator drugs were discontinued at least
24 hours before the initiation of the study.
Central hemodynamic measurements and computa-
tions. Right atrial and pulmonary arterial wedge pressures
were measured with a balloon-tipped, triple lumen catheter
(Swan-Ganz). Pressures were recorded on an Electronics
for Medicine VR-6 recorder; mean pressures were obtained
with the use of electronic integration. Systemic arterial blood
pressure was obtained by cuff and mercury column sphyg-
momanometer. Cardiac output was determined by the ther-
modilution technique as previously described (9). Derived
hemodynamic variables were calculated as follows: mean
arterial blood pressure (mm Hg) = (systolic blood pressure
- diastolic blood pressure) -:- 3 + diastolic blood pressure;
systemic vascular resistance (dynes-s-cm - 5) = 80 (mean
blood pressure - mean right atrial pressure) -:- cardiac
output.
Renal hemodynamic measurements and computa-
tions. Renal hemodynamic measurements were performed
with the patient in the supine position. The sodium para-
aminohippurate infusion technique was used to measure ef-
fective renal plasma flow, and glomerular filtration rate was
measured from the clearance of inulin (10). Intravenous
doses of 4 mg/kg body weight of sodium para-aminohip-
purate (Merck, Sharp, & Dohme) and 40 mg/kg of inulin
(American Critical Care) were followed by sustained in-
fusion of both drugs. Sodium para-arninohippurate (36 mg/ml)
was given at a rate of 0.3 ml/min for at least 3 hours. The
infusion rate for inulin was calculated to maintain constant
blood concentration. To achieve this the inulin rate must
equal the rate of loss in the urine and, thus, the amount
filtered by the kidney. In each patient , glomerular filtration
rate was estimated from body surface area and from the
previously determined serum creatine kinase (I I) . The rate
of inulin infusion was obtained by multiplying the value for
estimated glomerular filtration rate by 0.2 (plasma inulin
concentration in mg/ml). The clearance of inulin or sodium
para-aminohippurate was calculated by dividing the amount
of the drug infused per minute by its average steady state
concentration.
Renal bloodfiow (mllmin] was derived as effective renal
plasma flow/(I- hematocrit). Filtration fraction was derived
from the glomerular filtration rate/renal plasma flow ratio.
Renal vascular resistance (dynes-s-cm- 5) = 80 (mean blood
pressure - mean right atrial pressure) -:- renal blood flow.
In addition, the relative renal perfusion or the fraction of
the cardiac output going to the kidneys was calculated as
renal blood flow -:- cardiac output , and relative renal vas-
cular resistance as the renal vascular resistance/systemic
vascular resistance ratio.
Study protocol. Hemodynamic stability « 10% vari-
ation) in heart rate, blood pressure , pulmonary artery wedge
pressure and cardiac output was ensured for at least I hour
by two or more hemodynamic measurements . The values
obtained by the last measurement were reported as baseline.
Renal blood flow and glomerular filtration rate were mea-
sured every 15 minutes for 1 hour during stable hemody-
namic measurements and then every I minute for 3 minutes
immediately after control central hemodynamic determi-
nation. The average of all seven measurements was reported
as the control value. After baseline central and renal hemo-
dynamic determinations were completed , 20 mg of oral
nifedipine was administered and was followed by repeated
central hemodynamic measurements at 30 and 60 minutes .
An additional 10 mg of oral nifedipine was given at hourly
intervals when reduction of systemic vascular resistance (2:
25%) was not achieved. The total dose of nifedipine , there-
fore, ranged between 20 and 80 mg (mean 34 ± 22). The
determination of renal hemodynamic values was repeated
three times at 1 minute intervals 60 minutes after the admin-
istration of nifedipine at the time of central hemodynamic
measurement.
In eight ofour patients, an additional evaluation ofcen-
tral and renal hemodynamic response to hydralazine was
performed. The two drugs were given in a randomized cross-
over design . Oral nifedipine was given as the first drug in
three patients, while intravenous hydralazine was admin-
istered first in five patients. A washout period of at least 16
hours after the administration of the first drug was utilized
before the other drug was given to allow the return of hemo-
dynamic values to baseline. Hydralazine was given intra-
venously, starting with a dose of 2.5 mg. The dose was
then increased in increments of 2.5 to 5.0 mg every 20
minutes (mean dose 10 ± 5) until a reduction in systemic
vascularresistancegreater than or equal to 25% was achieved.
Data analysis. The central and renal hemodynamic ef-
fects and percent change from control after nifedipine and
hydralazine therapies were analyzed using the paired t test.
Regression analysis was used to correlate changes in renal
blood flow and changes in cardiac output after therapy. All
group values were expressed as mean ± standard deviation
of the mean.
Results
Central and renal hemodynamic effects of nifedipine
(Table 1, Fig. 1). Nifedipine therapy in nine patients re-
sulted in a significant decrease in systemic vascular resist-
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Table 1. Central and Renal Hemodynamic Data Before and After Nifedipine in Nine Patients With Congestive Heart Failure
MBP CO SVR RVR RVR/SVR RBF RBF/CO GFR FF
Case C NIF C NIF C NIF C NIF C NIF C NIF C NIF C NIF C NIF
1 90 83 4.6 5.1 1,524 1,250 9,751 7,574 6.4 6,0 722 845 0.16 0,16 61 53 14 10
2 92 88 3.5 4.2 1,914 1,506 10,468 12,284 7,3 8,2 472 521 0.14 0.12 60 56 23 19
3 95 90 3.5 3,6 1,745 1,489 10,284 10,388 5.9 7.0 599 516 0.17 0.14 97 87 25 26
4 107 97 2.8 3.7 2,076 1,792 15,729 16,907 5.9 9.4 473 388 0.17 0,11
5 90 79 6,5 7.8 1,009 728 8,735 8,126 8.7 11.2 751 699 0.12 0,9 79 86 19 22
6 94 92 4.1 5.2 1,720 1.241 12,234 11,590 7.1 9.3 582 566 0.14 0,11 56 54 14 14
7 117 83 4.7 5.5 1,842 1,173 11,339 7,385 6,2 6.3 769 845 0,16 0,15 47 42 II 9
8 81 79 3.7 4.6 1,594 1,184 11,918 9,262 7.5 7.8 490 596 0,13 0.13 47 49 17 14
9 94 93 4.3 4.6 1,704 1,525 13,835 9,059 8, I 5.9 532 786 0,12 0.17 47 68 19 19
Mean 96 87 4.2 4.9 1,748 1,321 11,988 10,286 7,0 7.9 599 640 0,15 0.13 62 62 18 17
± SO II 6 1.1 1.2 436 302 2,556 3,011 1.0 1.8 120 162 0,02 0.03 18 17 5 6
p value <0.05 <0,001 <0.001 <0,05 NS NS NS NS NS
C ~ control; CO = cardiac output (liters/min); FF = filtration fraction (%); GFR = glomerular filtration rate (ml/min); MBP = mean arterial blood
pressuv (mm Hg); NIF = nifedipine; NS = not significant; p = probability; RBF = renal blood flow (mllmin); RVR = renal vascular resistance
(dyne";'cm 5) ; SO = standard deviation; SVR = systemic vascular resistance (dynes-s-cmt ').
ance from 1,748 ± 436 to 1,321 ± 302 dynes-s-cm"? (p
< O.I)()!) and mean blood pressure from 96 ± 11 to 87 ±
6 mm Hg (p < 0,05), These changes were accompanied by
an increase in cardiac output from 4,2 ± 1.1 to 4,9 ± 1.2
liters min (p < 0.001). There was no significant change in
mean right atrial pressure (8 ± 5 versus 10 ± 6 mm Hg)
and mean pulmonary artery wedge pressure (21 ± 7 versus
21 ± 7 mm Hg).
Nitedipine administration was accompanied by a de-
crease in renal vascular resistance in seven patients, which
led to a significant change in the group mean value from
11,988 ± 2,256 to 10,286 ± 3,011 dynes-s-cm-5 (p <
0.05). Because the decrease in renal vascular resistance was
similar to that in systemic resistance, no significant change
was noted in the ratio between these two variables (7.0 ±
1.0 versus 7.9 ± 1.8). In spite of a marked decrease in
renal vascular resistance, renal blood flow demonstrated a
variable individual response with only a small and insig-
nificant increase of the mean value from 599 ± 120 to 640
± 162 mllmin. The ratio between renal blood flow and
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Figure 1. Graphic depiction of the effect of nifed- Nag Nag Na'
ipine (NIF) on renal blood flow, renal vascular re-
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tion. C = control; NS = not significant. (percent)0.20 15 30
-
-
0.15 !~I 10 !~! 20 I~I0.10 ~ 5 10
NS NS NSNo9 Nag Na'
NIFo cNIFcNIFC
0.05'--'-----L...-
1264 ELKAYAM ET AL.
RENAL HEMODYNAMIC EFFECTS OF VASODILATION
lACC Vol. 4. No.6
December 1 9~4 :1261 -7
Table 2. Central and Renal Hemodynamic Data Before and After Hydralazine in Eight Patients With Congestive Heart Failure
MBP CO SVR RVR RVRISVR RBF RBF/CO GFR FF
Case C Hyd C Hyd C Hyd C Hyd C Hyd C Hyd C Hyd C Hyd C Hyd
2 82 81 3.0 4.6 1,784 1,140 12,861 1,176 7 .2 10.3 423 449 0 .14 0. 10
3 97 94 3.4 4.7 1,825 1,291 11,325 9,697 6.2 7.5 551 627 0 . 16 0.13
4 106 96 2.8 3.9 2,526 1,600 17,734 13,709 7.0 8.6 406 461 0 .14 0.12
5 75 71 4.6 6.2 1.172 815 7.244 5,676 6.2 7.0 751 888 0.16 0.14 78 67 19 14
6 90 86 4 .3 5.7 1,589 LI57 11,724 10,5 13 7.4 9. 1 580 624 0.13 0.11 71 67 18 16
7 118 103 4.5 6 .3 1,942 1,225 10,481 8,421 5.4 6.9 832 912 0.18 0.14 53 52 12 11
8 75 78 3.8 5 .6 1,455 1.085 12.174 10,969 8.4 10.1 460 547 0 . 12 0.10 49 57 19 i8
9 93 87 4.2 5.4 1,721 1,259 13,094 10,478 7.6 8.3 556 649 0 .13 0.12 33 41 13 14
Mean 92 87 3.8 5.3 1,752 1,196 12,080 10,153 6.9 8.5 570 645 0 . \5 0 .12 57 57 16 15
:!: SD 15 10 0.7 0 .8 395 220 2,934 2,372 0.9 1.3 152 174 0.02 0 .02 18 11 3 3
p value < 0.05 < 0.00 1 <0.001 <0.001 <0.001 <0.001 < 0.00 1 NS NS
Hyd = hydralazine; other abbreviations as in Table I.
cardiac output decreased in seven patients ; the group mean
change, however, did not reach statistica l significance (0.15
± 0.02 versus 0 . 13 ± 0.03). Glomerular filtration rate and
the ratio between this variable and renal plasma flow (fil-
tration fraction) were evaluated in eight patients , and did
not change significantly after administration of nifedipine
(62 ± 18 versus 62 ± 17 ml/min and 18 ± 5 versus 17
± 6%, respectively).
Central and renal hemodynamic effects of hydrala-
zine. The administration of intravenous hydralazine to eight
of the patients resulted in a decrease in systemic vascular
resistance from 1,752 ± 395 to 1,196 ± 220dynes 's'cm- 5
(p < 0.00 I), an increase in cardiac output from 3.8 ± 0. 7
to 5.3 ± 0.8 liters/min (p < 0.001) and a decrease in mean
blood pressure from 92 ± 15 to 87 ± 10 mm Hg (p <
0.05) (Table 2). Only small and insignificant changes were
noted in mean right atrial pressure (from 10 ± 6 to 9 ± 6
mm Hg) and mean pulmonary artery wedge pressure (from
24 ± 6 to 22 ± 7 mm Hg).
The changes in central hemodynamics were accompanied
by a decrease in renal vascular resistance in each of the
patients (Fig . 2), with a decrease of the group mean value
from 12,080 ± 2,934 to 10,153 ± 2,372 dynes-s-cm 5 (p
< 0.001). However, the ratio of renal to systemic vascular
resistance increased significantly from 6.9 ± 0.9 to 8.5 ±
1.3 (p < 0.001) . This change in renal vascular resistance
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Figure 2. Graphic depiction of the effect of hy-
P <O .OOl P <O.OO l NS dralazine (HYD) on renal blood flow, renal vascular
N: 8 N=8 N=5 resistance, glomerular filtration rate, the ratio be-
0 2000 0 tween renal blood flow and cardiac output (RBF/CO),
C HYD C HYD C HYD the ratio between renal and systemic vascular re-
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sistance (RVR/SV R) and filtration fraction. Other
RBF/CO RVR/SVR abbreviations as in Figure I .
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Figure 3. Correlation between percent change from
baseline (%d ) incardiacoutputand renalbloodflow
after therapywith nifedipine (NIF)and hydralazine
(HYD).
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resulted in augmentation of renal blood flow in all patient s,
with an increase of mean value from 570 ± 152 to 645
± 174 ml/min, (p < 0.001) . In spite of the significant
improvement in renal blood flow, the ratio between this
variable and total cardiac output showed a substantial de-
crease from 0.15 ± 0.02 to 0.12 ± 0.02 (p < 0.001); that
is, the increase in renal blood flow (13%) was proportion-
ately less than the increase in cardiac output (39%). In
addition, the augmentation of blood flow was not associated
with a significant change in glomerular filtration rate or
filtration fraction (Table 2).
Figure 3 demonstrates the relation between percent change
in cardiac output and in renal blood flow. Poor correlation
was found between these variables after the admini stration
of nifedipine (r = -0. 29) and hydralazine (r = -0.32).
Discussion
Our data confirm the findings of previous studies (2-5)
and demonstrate a reducti on in rest renal blood flow in
patients with severe heart failure . Renal perfusion accounts
for approximately 20% of cardiac output in the normal pop-
ulation q2} . Flow to the renal circulation accounted for
only 15% of the cardiac output in our patients, substantiating
a preferential decrease in renal blood flow in severe heart
failure as part of the cardiovascular adjustment to maintain
adequate blood supply to the myocardium and the brain
(13).
Nifedipine effects. Several vasodilator agents such as
nitropru sside (3), hydral azine (14 ), captopril (6) and am-
rinone (15) have been demonstrated to improve renal blood
flow in patients with chronic congestive heart failure. At
the same time, other drug s such as isosorbide dinitrate,
nitroglycerin and prazo sin have been shown to have no
effect on the renal circulation in spite of a marked improve-
ment in central hemodynamic variables (4, 16) . Our study
confirms previous report s (3, 14, 16) which demonstrated an
augmentation of renal blood flow after arterial dilation with
hydralazine. This study also shows that vasodilation due to
calcium antagonism with nifedip ine in the same patients
resulted in no significant change in renal blood flow despite
a decrease in both systemic and renal vascular resistance
and a concomitant increase in cardiac output.
The strong effe ct of nifedipine 0 11 systemic vascular re-
sistance in patients with heart f ailure is consistent with
previous observations by other investigators and ourselves
(7,8, 17.18). Like othe r calcium channel blocking drugs,
nifedipine has been shown to exert a spec ific dilatory effect
on the coronary circulation (19) . Our data demonstrate that
nifedipine can also decrease renal vascular resistance in most
patient s with chronic conge stive heart failure. However, the
absence of any significant change in the ratio between renal
and systemic vascular resistance after therapy suggests that
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this drug does not have a preferential renal vasodilatory
effect. Failure of nifedipine to increase renal blood flow
despite a significant decrease in renal vascular resistance as
shown in this investigation is supported by a preliminary
study (20) showing an increase of hepatic and limb flow
with nifedipine in patients with heart failure without a change
in renal flow. This finding might be explained by the only
moderate increase in cardiac output, which does not fully
compensate for the reduction in systemic vascular resistance
leading to a decline in systemic arterial pressure (Table 1).
The limited augmentation in cardiac output after left ven-
tricular afterload reduction with nifedipine has been dem-
onstrated before (8,21,22) and is probably related to the
intrinsic negative inotropic effect of the drug.
Glomerular filtration rate was depressed in our patients
when compared with that in the normal population (11).
The value of this variable in our study was lower than in
other reports (3,5,23) and is probably explained by differ-
ences in the severity of heart failure, methods for measure-
ment and study design. The administration of nifedipine did
not improve and even decreased glomerular filtration rate
in half of the patients (Fig. 1). This fact could be related
to a decrease in renal perfusion pressure as a result of low-
ered renal vascular resistance without an adequate compen-
satory increase in blood flow.
Hydralazine effects. The short-term central and renal
hemodynamic effects of hydralazine in our patients are sim-
ilar to those previously reported (3,16,24). Hydralazine
therapy resulted in a significant reduction of the elevated
renal vascular resistance and allowed an increase in renal
blood flow in every patient. The augmentation of renal blood
flow was significantly smaller than that of the cardiac output
in our patients. This finding is somewhat at variance with
data reported by Magorien et al. (16), who found an increase
in renal blood flow with hydralazine that was proportionate
to the increase in cardiac output. The explanation for this
discrepancy is not clear. However, our data may suggest
that in spite of an increase in total renal blood flow, there
is a decrease in the proportion of blood flow to the kidneys.
Although the response of glomerular filtration rate to
hydralazine was studied in only five patients, our results are
in agreement with previous reports (3,23) demonstrating an
absence of improvement in filtration rate despite a substan-
tial augmentation in renal flow. A similar failure of glo-
merular filtration rate to respond to a substantial increase in
renal blood flow was reported by Creager et al. (5), who
studied the renal effect of converting enzyme inhibition in
patients with heart failure. A possible explanation for these
findings is that a significant decrease in arterial blood pres-
sure with both hydralazine (3) and captopril (5) may min-
imize the potential effect of increased flow to the glomeruli
and prevents an increase in the rate of filtration.
The effect of hydralazine on both the central and renal
hemodynamics has been shown to be dose-related (16,25).
For this reason, an attempt to compare the effects of nifed-
ipine with those of hydralazine should be limited to the dose
used in this study. Nevertheless, in our patients hydralazine
improved renal perfusion, while nifedipine in relatively high
doses failed to increase renal blood flow in spite of a similar
reduction in renal vascular resistance with both drugs.
Leithe et al. (2) recently reported a relation between the
depression of renal blood flow and cardiac output in patients
with heart failure. We could not find a similar correlation
. '
between changes in renal blood flow and changes in total
cardiac output after left ventricular afterload-reducing ther-
apy in the present study. These data suggest that the effect
of arterial dilation on renal flow is not solely dependent on
the increase in total cardiac output and that other factors,
such as individual changes in blood pressure and variability
in response of the renal and other circulatory regions to
vasodilator therapy, must also playa role.
Conclusion. This study identified the renal hemody-
namic consequences of vasodilation by nifedipine in patients
with severe chronic congestive heart failure. The adminis-
tration of nifedipine resulted in a marked reduction in sys-
temic vascular resistance associated with augmentation of
cardiac output in most patients. Abnormally elevated renal
vascular resistance decreased after nifedipine, without caus-
ing a significant improvement in renal blood flow or glo-
merular filtration rate. The administration of hydralazine to
the same patients resulted in a larger increase in cardiac
output and renal blood flow in all patients. However, the
increase in renal perfusion after hydralazine was propor-
tionately less than that of the total cardiac output and, like
nifedipine, did not affect glomerular filtration rate.
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